lnterferon-α treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy

Journal of Infectious Diseases

Volumn 175, Issue 6, 1997, Pages 1294-1301

  Zhang, Zhu Xu ^b   Milich, David R ^b   Peterson, Darrell L ^b   Birkett, Ashley ^b   Schvarcz, Robert ^b   Weiland, Ola ^b   Sällberg, Matti ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; RIBAVIRIN; ANTIVIRUS AGENT; GAMMA INTERFERON; HEPATITIS C ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; NS3 PROTEIN, HEPATITIS C VIRUS; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ADULT; ANTIGEN PRESENTATION; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HELPER CELL; HEPATITIS C; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; BLOOD; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS C VIRUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0030612409     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516459     Document Type: Article

References (23)

1. Inaba K, Kitaura M, Kato T, Watanabe Y, Kawade Y, Muramatsu S. Contrasting effect of alpha/beta- and gamma-interferons on expression of macrophage Ia antigens. J Exp Med 1986;163:1030-5.
2. Kelley VE, Fiers W, Strom TB. Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol 1984;132:240-5.
3. Ling PD, Warren MK, Vogel SN. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol 1985;135:1857-63.
4. + T cells. J Clin Invest 1996;97:309-15.
5. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996;272:1947-50.
6. Bartenschlager R, Ahlborn LL, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993;67:3835-44.
7. Bartenschlager R, Lohmann V, Wilkinson T, Koch JO. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4a and its importance for polyprotein maturation. J Virol 1995;69:7519-28.
8. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second hepatitis C virus - encoded proteinase. Proc Natl Acad Sci USA 1993;90:10583-7.
9. Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993;67:4017-26.
10. Jin L, Peterson DL. Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Arch Biochem Biophys 1995;323:47-53.
11. Lok AS, Chien D, Choo QL, et al. Antibody response to core, envelope, and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993;18:497-502.
12. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-7.
13. + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 1995;21:632-8.
14. Botarelli P, Brunetto MR, Minutello MA, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993;104:580-7.
15. Lerouxroels G, Esquivel CA, Deleys R, et al. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alpha. Hepatology 1996;23:8-16.
16. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996;98:706-14.
17. S̈allberg M, Zhang ZX, Chen M, et al. Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. J Gen Virol 1996;77:2721-8.
18. Weiner AJ, Brauer MJ, Rosenblatt J, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991;180:842-8.
19. Zhang ZX, Chen M, Weiland O, Sönnerborg A, Sällberg M. Distinguishing acute from symptomatic chronic hepatitis C virus (HCV) infection by site directed serology of the HCV structural proteins. J Infect Dis 1995;171:1356-9.
20. Milich DR, Peterson DL, Schödel F, Jones JE, Hughes JL. Preferential recognition of hepatitis B nucleocapsid antigens by Th1 and Th2 cells is epitope and major histocompatibility complex dependent. J Virol 1995;69:2776-85.
21. + T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993;178:17-25.
22. + T cell recruitment into tissue. J Immunol 1994;153:1264-70.
23. Shenoy M, Baron S, Wu B, Goluszko E, Christadoss P. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis. J Immunol 1995;154:6203-8.